Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-705 Monotherapy and Combination in Advanced HER2-Expressing Solid Tumors
NCT07022002Phase 2Recruiting
- Sponsor
- 3SBio
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-705 in gastric cancer (GC), breast cancer, non-small cell lung cancer (NSCLC), gastroesophageal junction cancer, sponsored by 3SBio. Started Jul 2025; status: recruiting.
02
Drugs
SSGJ-705
03
Conditions
gastric cancer (GC)breast cancernon-small cell lung cancer (NSCLC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07022002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022002.